Does the media refer more to ALMS or ELAN?

In the previous week, Elanco Animal Health had 6 more articles in the media than Alumis. MarketBeat recorded 10 mentions for Elanco Animal Health and 4 mentions for Alumis. Elanco Animal Health's average media sentiment score of 1.38 beat Alumis' score of 1.08 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, ALMS or AXSM?

Axsome Therapeutics has higher revenue and earnings than Alumis. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alumis $8.40M 432.31 -$243.32M -$1.98 N/A Axsome Therapeutics $638.50M 19.26 -$183.17M -$3.73 N/A

Is ALMS or AXSM more profitable?

Axsome Therapeutics has a net margin of -26.59% compared to Alumis' net margin of -2,825.70%. Alumis' return on equity of -88.79% beat Axsome Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alumis -2,825.70% -88.79% -70.72% Axsome Therapeutics -26.59% -267.16% -28.53%

Does the media prefer ALMS or AXSM?

In the previous week, Axsome Therapeutics had 10 more articles in the media than Alumis. MarketBeat recorded 14 mentions for Axsome Therapeutics and 4 mentions for Alumis. Alumis' average media sentiment score of 1.08 beat Axsome Therapeutics' score of 0.68 indicating that Alumis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 4 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, ABVX or ALMS?

Alumis has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Alumis $8.40M 432.31 -$243.32M -$1.98 N/A

Is ABVX or ALMS more profitable?

Abivax has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Alumis' return on equity of -88.79% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Alumis -2,825.70% -88.79% -70.72%

Does the media favor ABVX or ALMS?

In the previous week, Abivax and Abivax both had 4 articles in the media. Abivax's average media sentiment score of 1.44 beat Alumis' score of 1.08 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alumis 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SMMT or ALMS more profitable?

Summit Therapeutics has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Alumis' return on equity of -88.79% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -291.24% -243.07% Alumis -2,825.70% -88.79% -70.72%

Does the media refer more to SMMT or ALMS?

In the previous week, Summit Therapeutics had 2 more articles in the media than Alumis. MarketBeat recorded 6 mentions for Summit Therapeutics and 4 mentions for Alumis. Alumis' average media sentiment score of 1.08 beat Summit Therapeutics' score of 0.42 indicating that Alumis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alumis 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ALMS or RDY?

Alumis currently has a consensus price target of $40.30, indicating a potential upside of 41.45%. Given Alumis' stronger consensus rating and higher probable upside, equities research analysts clearly believe Alumis is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alumis 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.83 Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Does the media prefer ALMS or RDY?

In the previous week, Dr. Reddy's Laboratories had 3 more articles in the media than Alumis. MarketBeat recorded 7 mentions for Dr. Reddy's Laboratories and 4 mentions for Alumis. Alumis' average media sentiment score of 1.08 beat Dr. Reddy's Laboratories' score of 0.67 indicating that Alumis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive

Alumis (ALMS) Competitors

$28.49 -1.56 (-5.19%)

As of 01:44 PM Eastern

Compare

ALMS vs. ELAN, AXSM, ABVX, SMMT, and RDY

Should you buy Alumis stock or one of its competitors? MarketBeat compares Alumis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alumis include Elanco Animal Health (ELAN), Axsome Therapeutics (AXSM), Abivax (ABVX), Summit Therapeutics (SMMT), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry.

How does Alumis compare to Elanco Animal Health?

Alumis (NASDAQ:ALMS) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Elanco Animal Health has a net margin of -4.95% compared to Alumis' net margin of -2,825.70%. Elanco Animal Health's return on equity of 7.42% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-2,825.70%	-88.79%	-70.72%
Elanco Animal Health	-4.95%	7.42%	3.66%

In the previous week, Elanco Animal Health had 6 more articles in the media than Alumis. MarketBeat recorded 10 mentions for Elanco Animal Health and 4 mentions for Alumis. Elanco Animal Health's average media sentiment score of 1.38 beat Alumis' score of 1.08 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alumis currently has a consensus price target of $40.30, suggesting a potential upside of 41.45%. Elanco Animal Health has a consensus price target of $28.55, suggesting a potential upside of 10.45%. Given Alumis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Alumis is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Alumis has a beta of -0.73, meaning that its share price is 173% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, meaning that its share price is 68% more volatile than the broader market.

Elanco Animal Health has higher revenue and earnings than Alumis. Elanco Animal Health is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$8.40M	432.31	-$243.32M	-$1.98	N/A
Elanco Animal Health	$4.89B	2.64	-$232M	-$0.50	N/A

97.5% of Elanco Animal Health shares are held by institutional investors. 33.7% of Alumis shares are held by insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Elanco Animal Health beats Alumis on 10 of the 15 factors compared between the two stocks.

How does Alumis compare to Axsome Therapeutics?

Alumis (NASDAQ:ALMS) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Axsome Therapeutics has a net margin of -26.59% compared to Alumis' net margin of -2,825.70%. Alumis' return on equity of -88.79% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-2,825.70%	-88.79%	-70.72%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

81.5% of Axsome Therapeutics shares are held by institutional investors. 33.7% of Alumis shares are held by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Alumis has a beta of -0.73, suggesting that its share price is 173% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market.

In the previous week, Axsome Therapeutics had 10 more articles in the media than Alumis. MarketBeat recorded 14 mentions for Axsome Therapeutics and 4 mentions for Alumis. Alumis' average media sentiment score of 1.08 beat Axsome Therapeutics' score of 0.68 indicating that Alumis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	4 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alumis presently has a consensus price target of $40.30, suggesting a potential upside of 41.45%. Axsome Therapeutics has a consensus price target of $261.48, suggesting a potential upside of 9.43%. Given Alumis' higher probable upside, analysts clearly believe Alumis is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Axsome Therapeutics	2 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.91

Axsome Therapeutics has higher revenue and earnings than Alumis. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$8.40M	432.31	-$243.32M	-$1.98	N/A
Axsome Therapeutics	$638.50M	19.26	-$183.17M	-$3.73	N/A

Summary

Axsome Therapeutics beats Alumis on 10 of the 17 factors compared between the two stocks.

How does Alumis compare to Abivax?

Abivax (NASDAQ:ABVX) and Alumis (NASDAQ:ALMS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

Abivax has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Alumis' return on equity of -88.79% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Alumis	-2,825.70%	-88.79%	-70.72%

Abivax currently has a consensus target price of $148.54, indicating a potential upside of 14.29%. Alumis has a consensus target price of $40.30, indicating a potential upside of 41.45%. Given Alumis' stronger consensus rating and higher probable upside, analysts plainly believe Alumis is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Abivax and Abivax both had 4 articles in the media. Abivax's average media sentiment score of 1.44 beat Alumis' score of 1.08 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alumis	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Abivax has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, Alumis has a beta of -0.73, suggesting that its stock price is 173% less volatile than the broader market.

47.9% of Abivax shares are owned by institutional investors. 33.7% of Alumis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Alumis has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Alumis	$8.40M	432.31	-$243.32M	-$1.98	N/A

Summary

Alumis beats Abivax on 9 of the 15 factors compared between the two stocks.

How does Alumis compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Alumis (NASDAQ:ALMS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

In the previous week, Summit Therapeutics had 2 more articles in the media than Alumis. MarketBeat recorded 6 mentions for Summit Therapeutics and 4 mentions for Alumis. Alumis' average media sentiment score of 1.08 beat Summit Therapeutics' score of 0.42 indicating that Alumis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alumis	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summit Therapeutics has a beta of -1.26, suggesting that its stock price is 226% less volatile than the broader market. Comparatively, Alumis has a beta of -0.73, suggesting that its stock price is 173% less volatile than the broader market.

Summit Therapeutics presently has a consensus target price of $26.97, suggesting a potential upside of 82.06%. Alumis has a consensus target price of $40.30, suggesting a potential upside of 41.45%. Given Summit Therapeutics' higher probable upside, analysts plainly believe Summit Therapeutics is more favorable than Alumis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summit Therapeutics has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Alumis' return on equity of -88.79% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
Alumis	-2,825.70%	-88.79%	-70.72%

Alumis has higher revenue and earnings than Summit Therapeutics. Alumis is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
Alumis	$8.40M	432.31	-$243.32M	-$1.98	N/A

4.6% of Summit Therapeutics shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by insiders. Comparatively, 33.7% of Alumis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Alumis beats Summit Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Alumis compare to Dr. Reddy's Laboratories?

Alumis (NASDAQ:ALMS) and Dr. Reddy's Laboratories (NYSE:RDY) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

Alumis has a beta of -0.73, indicating that its stock price is 173% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market.

Alumis currently has a consensus price target of $40.30, indicating a potential upside of 41.45%. Given Alumis' stronger consensus rating and higher probable upside, equities research analysts clearly believe Alumis is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Dr. Reddy's Laboratories has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$8.40M	432.31	-$243.32M	-$1.98	N/A
Dr. Reddy's Laboratories	$335.93B	0.03	$456M	$0.58	19.93

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Alumis' net margin of -2,825.70%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-2,825.70%	-88.79%	-70.72%
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%

3.8% of Dr. Reddy's Laboratories shares are owned by institutional investors. 33.7% of Alumis shares are owned by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Dr. Reddy's Laboratories had 3 more articles in the media than Alumis. MarketBeat recorded 7 mentions for Dr. Reddy's Laboratories and 4 mentions for Alumis. Alumis' average media sentiment score of 1.08 beat Dr. Reddy's Laboratories' score of 0.67 indicating that Alumis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Dr. Reddy's Laboratories beats Alumis on 10 of the 17 factors compared between the two stocks.

Get Alumis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALMS vs. The Competition

Export

Metric	Alumis	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.63B	$3.64B	$6.80B	$12.40B
Dividend Yield	N/A	2.18%	2.67%	9.67%
P/E Ratio	-14.37	21.06	26.91	24.05
Price / Sales	432.31	163.39	503.34	91.67
Price / Cash	N/A	150.24	49.71	59.37
Price / Book	9.89	8.03	10.61	6.19
Net Income	-$243.32M	$23.81M	$3.60B	$331.71M
7 Day Performance	-1.11%	-3.40%	-2.02%	-1.63%
1 Month Performance	15.81%	-0.81%	0.27%	-2.17%
1 Year Performance	760.73%	41.59%	22.74%	17.68%

Alumis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALMS Alumis	3.4405 of 5 stars	$28.49 -5.2%	$40.30 +41.5%	+805.1%	$3.63B	$8.40M	N/A	N/A	Positive News
ELAN Elanco Animal Health	3.7275 of 5 stars	$25.84 -0.4%	$28.55 +10.5%	+73.6%	$12.96B	$4.72B	N/A	9,400	News Coverage Positive News
AXSM Axsome Therapeutics	3.4189 of 5 stars	$230.00 -3.0%	$259.05 +12.6%	+116.0%	$12.20B	$638.50M	N/A	380	Analyst Upgrade
ABVX Abivax	2.7892 of 5 stars	$136.65 -0.8%	$148.54 +8.7%	+1,222.4%	$10.99B	N/A	N/A	61
SMMT Summit Therapeutics	3.447 of 5 stars	$13.81 +0.4%	$26.97 +95.3%	-44.5%	$10.68B	N/A	N/A	110	News Coverage Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALMS) was last updated on 7/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alumis (ALMS) Competitors

ALMS vs. ELAN, AXSM, ABVX, SMMT, and RDY

How does Alumis compare to Elanco Animal Health?

Summary

How does Alumis compare to Axsome Therapeutics?

Summary

How does Alumis compare to Abivax?

Summary

How does Alumis compare to Summit Therapeutics?

Summary

How does Alumis compare to Dr. Reddy's Laboratories?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALMS vs. The Competition

Alumis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alumis (ALMS) Competitors

ALMS vs. ELAN, AXSM, ABVX, SMMT, and RDY

How does Alumis compare to Elanco Animal Health?

Is ALMS or ELAN more profitable?

Does the media refer more to ALMS or ELAN?

Do analysts rate ALMS or ELAN?

Which has more risk and volatility, ALMS or ELAN?

Which has higher earnings & valuation, ALMS or ELAN?

Do insiders & institutionals believe in ALMS or ELAN?

Summary

How does Alumis compare to Axsome Therapeutics?

Is ALMS or AXSM more profitable?

Do insiders and institutionals hold more shares of ALMS or AXSM?

Which has more risk and volatility, ALMS or AXSM?

Does the media prefer ALMS or AXSM?

Do analysts prefer ALMS or AXSM?

Which has better earnings and valuation, ALMS or AXSM?

Summary

How does Alumis compare to Abivax?

Is ABVX or ALMS more profitable?

Do analysts prefer ABVX or ALMS?

Does the media favor ABVX or ALMS?

Which has more risk & volatility, ABVX or ALMS?

Do insiders & institutionals believe in ABVX or ALMS?

Which has higher earnings and valuation, ABVX or ALMS?

Summary

How does Alumis compare to Summit Therapeutics?

Does the media refer more to SMMT or ALMS?

Which has more risk & volatility, SMMT or ALMS?

Do analysts recommend SMMT or ALMS?

Is SMMT or ALMS more profitable?

Which has better earnings & valuation, SMMT or ALMS?

Do insiders and institutionals hold more shares of SMMT or ALMS?

Summary

How does Alumis compare to Dr. Reddy's Laboratories?

Which has more risk & volatility, ALMS or RDY?

Do analysts rate ALMS or RDY?

Which has stronger earnings and valuation, ALMS or RDY?

Is ALMS or RDY more profitable?

Do insiders & institutionals have more ownership in ALMS or RDY?

Does the media prefer ALMS or RDY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALMS vs. The Competition

Alumis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools